JP2005511648A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005511648A5 JP2005511648A5 JP2003548782A JP2003548782A JP2005511648A5 JP 2005511648 A5 JP2005511648 A5 JP 2005511648A5 JP 2003548782 A JP2003548782 A JP 2003548782A JP 2003548782 A JP2003548782 A JP 2003548782A JP 2005511648 A5 JP2005511648 A5 JP 2005511648A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- group
- mixtures
- lipid
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 94
- 150000002632 lipids Chemical class 0.000 claims description 74
- 238000000034 method Methods 0.000 claims description 69
- 239000004094 surface-active agent Substances 0.000 claims description 45
- 239000003380 propellant Substances 0.000 claims description 42
- 239000003795 chemical substances by application Substances 0.000 claims description 40
- 150000003904 phospholipids Chemical class 0.000 claims description 40
- 239000013543 active substance Substances 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 102000004169 proteins and genes Human genes 0.000 claims description 25
- 239000013078 crystal Substances 0.000 claims description 24
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 21
- 150000001720 carbohydrates Chemical class 0.000 claims description 18
- 235000014633 carbohydrates Nutrition 0.000 claims description 18
- -1 neumogalactan Chemical compound 0.000 claims description 17
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 17
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical group FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 16
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 14
- 229920006395 saturated elastomer Polymers 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- BBJQPKLGPMQWBU-UHFFFAOYSA-N Palmitinsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCC)C2 BBJQPKLGPMQWBU-UHFFFAOYSA-N 0.000 claims description 9
- BBJQPKLGPMQWBU-JADYGXMDSA-N cholesteryl palmitate Chemical group C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCC)C1 BBJQPKLGPMQWBU-JADYGXMDSA-N 0.000 claims description 9
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 claims description 9
- 102000009027 Albumins Human genes 0.000 claims description 8
- 108010088751 Albumins Proteins 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- 229930091371 Fructose Natural products 0.000 claims description 7
- 239000005715 Fructose Substances 0.000 claims description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 7
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 7
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 claims description 7
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 claims description 7
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 claims description 7
- 239000008121 dextrose Substances 0.000 claims description 7
- 229930182830 galactose Natural products 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 239000003580 lung surfactant Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 230000001603 reducing effect Effects 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 73
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 16
- 239000002260 anti-inflammatory agent Substances 0.000 claims 16
- 229930182558 Sterol Natural products 0.000 claims 14
- 235000014113 dietary fatty acids Nutrition 0.000 claims 14
- 229930195729 fatty acid Natural products 0.000 claims 14
- 239000000194 fatty acid Substances 0.000 claims 14
- 150000004665 fatty acids Chemical class 0.000 claims 14
- 150000003432 sterols Chemical class 0.000 claims 14
- 235000003702 sterols Nutrition 0.000 claims 14
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 12
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 12
- 206010033078 Otitis media Diseases 0.000 claims 10
- 210000000613 ear canal Anatomy 0.000 claims 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 8
- 210000000959 ear middle Anatomy 0.000 claims 7
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims 6
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims 6
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 6
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 6
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims 6
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 6
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 6
- 239000005642 Oleic acid Substances 0.000 claims 6
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 6
- 235000021314 Palmitic acid Nutrition 0.000 claims 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 6
- 239000001569 carbon dioxide Substances 0.000 claims 6
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 6
- 235000012000 cholesterol Nutrition 0.000 claims 6
- 210000000981 epithelium Anatomy 0.000 claims 6
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims 6
- 230000000774 hypoallergenic effect Effects 0.000 claims 6
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 6
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 6
- 239000011647 vitamin D3 Substances 0.000 claims 6
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims 6
- 235000005282 vitamin D3 Nutrition 0.000 claims 6
- 229940021056 vitamin d3 Drugs 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 5
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims 4
- 239000003242 anti bacterial agent Substances 0.000 claims 4
- 229940088710 antibiotic agent Drugs 0.000 claims 4
- 229940098164 augmentin Drugs 0.000 claims 4
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 4
- 229960002537 betamethasone Drugs 0.000 claims 4
- 230000003115 biocidal effect Effects 0.000 claims 4
- 229960003276 erythromycin Drugs 0.000 claims 4
- 238000001415 gene therapy Methods 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical group CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims 4
- 229960001802 phenylephrine Drugs 0.000 claims 4
- 230000002708 enhancing effect Effects 0.000 claims 3
- 239000007921 spray Substances 0.000 claims 3
- 239000000443 aerosol Substances 0.000 claims 2
- 229960003022 amoxicillin Drugs 0.000 claims 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims 2
- 229940066294 lung surfactant Drugs 0.000 claims 2
- 229940071648 metered dose inhaler Drugs 0.000 claims 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims 2
- 210000003027 ear inner Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 description 9
- 229940079593 drug Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 description 1
- 108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- BIABMEZBCHDPBV-UHFFFAOYSA-N dipalmitoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/011,344 US6676930B2 (en) | 1999-11-28 | 2001-12-04 | Composition and method for treatment of otitis media |
| PCT/US2002/038366 WO2003047521A2 (en) | 2001-12-04 | 2002-11-29 | Composition and method for treatment of otitis media |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005511648A JP2005511648A (ja) | 2005-04-28 |
| JP2005511648A5 true JP2005511648A5 (https=) | 2006-02-09 |
Family
ID=21749979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003548782A Pending JP2005511648A (ja) | 2001-12-04 | 2002-11-29 | 中耳炎の処置のための組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US6676930B2 (https=) |
| EP (1) | EP1461090A4 (https=) |
| JP (1) | JP2005511648A (https=) |
| WO (1) | WO2003047521A2 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1608407T3 (pl) * | 2003-03-20 | 2006-12-29 | Pharmacia Corp | Dyspergowana kompozycja środka przeciw-zapalnego |
| US20050004098A1 (en) * | 2003-03-20 | 2005-01-06 | Britten Nancy Jean | Dispersible formulation of an anti-inflammatory agent |
| US20040214753A1 (en) * | 2003-03-20 | 2004-10-28 | Britten Nancy Jean | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| US20050009931A1 (en) * | 2003-03-20 | 2005-01-13 | Britten Nancy Jean | Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| US20070110788A1 (en) * | 2005-11-14 | 2007-05-17 | Hissong James B | Injectable formulation capable of forming a drug-releasing device |
| US20070173463A1 (en) * | 2006-01-20 | 2007-07-26 | Brechtelsbauer Paul B | Method and composition for treating otitis media |
| AU2007221150B2 (en) * | 2006-02-27 | 2012-09-20 | Ahm Technologies, Inc. | Eustachian tube device and method |
| US20070264296A1 (en) * | 2006-05-10 | 2007-11-15 | Myntti Matthew F | Biofilm extracellular polysachharide solvating system |
| US7959943B2 (en) * | 2006-05-10 | 2011-06-14 | Medtronics Xomed, Inc. | Solvating system and sealant for medical use in the middle or inner ear |
| US7976873B2 (en) * | 2006-05-10 | 2011-07-12 | Medtronic Xomed, Inc. | Extracellular polysaccharide solvating system for treatment of bacterial ear conditions |
| US7993675B2 (en) * | 2006-05-10 | 2011-08-09 | Medtronic Xomed, Inc. | Solvating system and sealant for medical use in the sinuses and nasal passages |
| EP2086617A4 (en) | 2006-10-26 | 2013-11-20 | Next Breath Llc | INHALATION SYSTEM BASED ON PHOSPHOLIPIDS |
| US8088095B2 (en) * | 2007-02-08 | 2012-01-03 | Medtronic Xomed, Inc. | Polymeric sealant for medical use |
| US20090197956A1 (en) * | 2008-02-04 | 2009-08-06 | Arbor Pharmaceuticals, Inc. | Treatment of acute otitis media with xylitol and n-acetylcysteine |
| CA2727432C (en) | 2008-06-12 | 2016-10-11 | Medtronic Xomed, Inc. | Method for treating chronic wounds with an extracellular polymeric substance solvating system |
| EP2346324A4 (en) | 2008-10-06 | 2012-10-10 | Microbial Defense Systems Llc | ANTIMICROBIAL COMPOSITION AND METHODS OF MAKING AND USING |
| US11033624B2 (en) | 2010-06-02 | 2021-06-15 | Novaflux Inc. | Medical item for prevention and treatment of ear infection |
| US10653133B2 (en) | 2011-05-10 | 2020-05-19 | Next Science IP Holdings Pty Ltd | Antimicrobial solid and methods of making and using same |
| WO2015168642A1 (en) | 2014-05-02 | 2015-11-05 | Labib Mohamed E | Drug-releasing device usable in mucosal body cavities |
| MX2018006575A (es) * | 2015-11-30 | 2018-12-06 | Novus Therapeutics Inc | Composiciones y metodos para profilaxis otologica y tratamiento. |
| EP3914323A4 (en) * | 2019-01-23 | 2022-10-05 | Alrich Partners, Inc. | METHOD FOR IMPROVING EUSTACHE POLE PERMEABILITY AND TREATMENT OF OTITIS MEDIA |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5141674A (en) | 1984-03-08 | 1992-08-25 | Phares Pharmaceutical Research N.V. | Methods of preparing pro-liposome dispersions and aerosols |
| JPH0753661B2 (ja) | 1984-03-08 | 1995-06-07 | フアレス フアーマスーチカル リサーチ エヌブイ | プロ―リポソーム組成物及びリポソームの水性分散物を作る方法 |
| GB8501015D0 (en) | 1985-01-16 | 1985-02-20 | Riker Laboratories Inc | Drug |
| DE3686025T2 (de) | 1985-05-22 | 1993-01-07 | Liposome Technology Inc | Verfahren und system zum einatmen von liposomen. |
| US4826821A (en) | 1985-06-26 | 1989-05-02 | The Regents Of The University Of California | Lung surfactant compositions |
| SE462894B (sv) | 1985-10-28 | 1990-09-17 | Biogram Ab | Mikrokapslar, foerfarande foer framstaellning daerav samt anvaendning |
| US5013720A (en) | 1986-05-06 | 1991-05-07 | Abbott Laboratories | SAP-6-Val proteins and methods |
| SE8603812D0 (sv) | 1986-09-12 | 1986-09-12 | Draco Ab | Administration of liposomes to mammals |
| CA1338736C (fr) | 1986-12-05 | 1996-11-26 | Roger Baurain | Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation |
| IT1203873B (it) | 1987-04-08 | 1989-02-23 | Chiesi Farma Spa | Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e |
| JP2656944B2 (ja) | 1987-04-30 | 1997-09-24 | クーパー ラボラトリーズ | タンパク質性治療剤のエアロゾール化 |
| US5260273A (en) | 1988-01-06 | 1993-11-09 | The Scripps Research Institute | Pulmonary surfactant protein and related polypeptide |
| JPH01258620A (ja) | 1988-04-08 | 1989-10-16 | Dai Ichi Seiyaku Co Ltd | 耳疾患用局所製剤 |
| MX9203504A (es) | 1988-04-20 | 1992-07-01 | Liposome Co Inc | Complejo agente: lipido activo de alta proporcion. |
| US4906476A (en) | 1988-12-14 | 1990-03-06 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs in lungs |
| US5134129A (en) | 1989-03-15 | 1992-07-28 | Board Of Regents, The University Of Texas System | Methods employing unique mixtures of polar and neutral lipids for surfactant replacement therapy |
| US5174988A (en) | 1989-07-27 | 1992-12-29 | Scientific Development & Research, Inc. | Phospholipid delivery system |
| US5238920A (en) | 1989-08-22 | 1993-08-24 | Abbott Laboratories | Pulmonary surfactant protein fragments |
| CA2108782C (en) | 1991-04-29 | 2002-05-07 | Joseph R. Di Bartolomeo | Composition and method for treatment of patulous eustachian tube syndrome and atrophic rhinitis |
| GB9120005D0 (en) | 1991-09-19 | 1991-11-06 | Wellcome Found | Method of administering phospholipid dispersions |
| IS1796B (is) | 1993-06-24 | 2001-12-31 | Ab Astra | Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband |
| DE4323636A1 (de) | 1993-07-15 | 1995-01-19 | Hoechst Ag | Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung |
| CA2213638C (en) | 1995-02-24 | 2004-05-04 | Nanosystems L.L.C. | Aerosols containing nanoparticle dispersions |
| AU5417796A (en) | 1995-03-07 | 1996-09-23 | University Of Pittsburgh | A dry powder formulation for gene therapy |
| US6129934A (en) | 1995-06-07 | 2000-10-10 | Ony, Inc. | Modification of animal lung surfactant for treating respiratory disease due to lung surfactant deficiency or dysfunction |
| WO1997029738A1 (en) | 1996-02-16 | 1997-08-21 | The Administrators Of The Tulane Educational Fund | Methods and compositions for treating eustachian tube dysfunction by inhalation |
| WO1997035882A1 (en) | 1996-03-27 | 1997-10-02 | Ortho Pharmaceutical Corporation | Lyophilized pulmonary surfactant peptide compositions |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| USRE37053E1 (en) | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| KR20000048812A (ko) | 1996-10-01 | 2000-07-25 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | 병원성 유기체에 의한 비인두 전이증식 관련 세균 감염 치료용약제를 제조하기 위한 뮤피로신의 용도 |
| US6143276A (en) | 1997-03-21 | 2000-11-07 | Imarx Pharmaceutical Corp. | Methods for delivering bioactive agents to regions of elevated temperatures |
| US5925334A (en) | 1997-08-27 | 1999-07-20 | Rubin; Bruce K. | Use of surface active agents to promote mucus clearance |
| US6309623B1 (en) | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| ES2191355T3 (es) * | 1997-12-24 | 2003-09-01 | Britannia Pharmaceuticals Ltd | Uso de un tensioactivo para la preparacion de un medicamento para el tratamiento de trastornos del oido medio. |
| US6200598B1 (en) | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
| US6297227B1 (en) | 1998-09-10 | 2001-10-02 | Schering Corporation | Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines |
| US6093417A (en) | 1999-01-11 | 2000-07-25 | Advanced Medical Instruments | Composition to treat ear disorders |
| US6156294A (en) * | 1999-11-28 | 2000-12-05 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis media |
| US7064132B2 (en) * | 1999-11-28 | 2006-06-20 | Scientific Development And Research, Inc. | Composition and method for treatment of otitis external |
| US6645467B2 (en) * | 1999-11-28 | 2003-11-11 | Scientific Development And Research, Inc. | Composition and method for decreasing upper respiratory airway resistance |
-
2001
- 2001-12-04 US US10/011,344 patent/US6676930B2/en not_active Expired - Lifetime
-
2002
- 2002-11-29 WO PCT/US2002/038366 patent/WO2003047521A2/en not_active Ceased
- 2002-11-29 EP EP02784684A patent/EP1461090A4/en not_active Withdrawn
- 2002-11-29 JP JP2003548782A patent/JP2005511648A/ja active Pending
-
2003
- 2003-06-27 US US10/608,166 patent/US20040001868A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005511648A5 (https=) | ||
| JP2003514842A (ja) | 中耳炎を処置する組成物及び方法 | |
| KR101926060B1 (ko) | 활성제의 호흡기 전달용 조성물, 및 연관된 방법 및 시스템 | |
| US5306483A (en) | Phospholipid delivery system | |
| JP5952231B2 (ja) | ドラッグ・デリバリー用の安定な金属イオン−脂質粉末状医薬組成物とその利用方法 | |
| JP2005511648A (ja) | 中耳炎の処置のための組成物および方法 | |
| ITMI971798A1 (it) | Formulazioni di aerosol medicinali | |
| JP2005537870A (ja) | 溶媒および薬学的成分を含浸した不活性基材を有する噴霧器 | |
| ITMI982558A1 (it) | Formulazioni di aerosol medicinali | |
| JP2002529393A (ja) | 吸入システム | |
| WO2015138423A9 (en) | Prostacylin compositions and methods for using the same | |
| KR20010014163A (ko) | 토코페롤로 안정화된 흡입용 프로리포좀 분말 | |
| JP6415536B2 (ja) | ブデソニドおよびフォルモテロールを含む医薬組成物 | |
| US7064132B2 (en) | Composition and method for treatment of otitis external | |
| US6645467B2 (en) | Composition and method for decreasing upper respiratory airway resistance | |
| Subramanian | Proliposome and Prosurfactosome Formulations for Pulmonary Drug Delivery | |
| Hidayat | Proniosome formulations for pulmonary drug delivery | |
| WO2009055788A1 (en) | Pneumoreductive therapy and compositions useful therein | |
| WO2003061668A1 (en) | Use of pulmonary surfactant for the prevention of infectious diseases |